Novel antigens of CAR T cell therapy: New roads; old destination
Chimeric antigen receptor T cell (CAR-T) therapy has so far proved itself as a reliable therapeutic option for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and mantle cell lymphoma (MCL). However...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-07-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523321000711 |
| _version_ | 1819090840346165248 |
|---|---|
| author | Pooria Safarzadeh Kozani Pouya Safarzadeh Kozani Fatemeh Rahbarizadeh |
| author_facet | Pooria Safarzadeh Kozani Pouya Safarzadeh Kozani Fatemeh Rahbarizadeh |
| author_sort | Pooria Safarzadeh Kozani |
| collection | DOAJ |
| description | Chimeric antigen receptor T cell (CAR-T) therapy has so far proved itself as a reliable therapeutic option for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and mantle cell lymphoma (MCL). However, this picture is not as colorful when it comes to the treatment of solid tumors mainly due to the lack of definitive tumor antigens, as well as the immunosuppressive tumor microenvironments and poor CAR-T infiltration. The recent developments in bioinformatics and cell biology, such as single-cell RNA sequencing, have offered silver linings in the subject of tumor antigen discovery. In the current review, we summarize the development of some CAR-T therapies that target novel tumor antigens, rather than the traditionally CAR-T-targeted ones, and briefly discuss the clinical antitumor achievements of those evaluated in patients, so far. Furthermore, we propose some tumor antigens that might someday be therapeutically beneficial while targeted by CAR-Ts based on the experimental evaluations of their specific monoclonal antibodies. |
| first_indexed | 2024-12-21T22:30:13Z |
| format | Article |
| id | doaj.art-48ad8659d2934b6a97124432bd81ffb4 |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-21T22:30:13Z |
| publishDate | 2021-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-48ad8659d2934b6a97124432bd81ffb42022-12-21T18:48:06ZengElsevierTranslational Oncology1936-52332021-07-01147101079Novel antigens of CAR T cell therapy: New roads; old destinationPooria Safarzadeh Kozani0Pouya Safarzadeh Kozani1Fatemeh Rahbarizadeh2Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IranDepartment of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran; Student Research Committee, Medical Biotechnology Research Center, School of Nursing, Midwifery, and Paramedicine, Guilan University of Medical Sciences, Rasht, IranDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; Research and Development Center of Biotechnology, Tarbiat Modares University, Tehran, Iran; Corresponding author at: Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, P.O. Box 14115/111, Iran.Chimeric antigen receptor T cell (CAR-T) therapy has so far proved itself as a reliable therapeutic option for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and mantle cell lymphoma (MCL). However, this picture is not as colorful when it comes to the treatment of solid tumors mainly due to the lack of definitive tumor antigens, as well as the immunosuppressive tumor microenvironments and poor CAR-T infiltration. The recent developments in bioinformatics and cell biology, such as single-cell RNA sequencing, have offered silver linings in the subject of tumor antigen discovery. In the current review, we summarize the development of some CAR-T therapies that target novel tumor antigens, rather than the traditionally CAR-T-targeted ones, and briefly discuss the clinical antitumor achievements of those evaluated in patients, so far. Furthermore, we propose some tumor antigens that might someday be therapeutically beneficial while targeted by CAR-Ts based on the experimental evaluations of their specific monoclonal antibodies.http://www.sciencedirect.com/science/article/pii/S1936523321000711Cancer immunotherapyAdoptive cell therapyCasMabTumor-associated antigensChimeric antigen receptor |
| spellingShingle | Pooria Safarzadeh Kozani Pouya Safarzadeh Kozani Fatemeh Rahbarizadeh Novel antigens of CAR T cell therapy: New roads; old destination Translational Oncology Cancer immunotherapy Adoptive cell therapy CasMab Tumor-associated antigens Chimeric antigen receptor |
| title | Novel antigens of CAR T cell therapy: New roads; old destination |
| title_full | Novel antigens of CAR T cell therapy: New roads; old destination |
| title_fullStr | Novel antigens of CAR T cell therapy: New roads; old destination |
| title_full_unstemmed | Novel antigens of CAR T cell therapy: New roads; old destination |
| title_short | Novel antigens of CAR T cell therapy: New roads; old destination |
| title_sort | novel antigens of car t cell therapy new roads old destination |
| topic | Cancer immunotherapy Adoptive cell therapy CasMab Tumor-associated antigens Chimeric antigen receptor |
| url | http://www.sciencedirect.com/science/article/pii/S1936523321000711 |
| work_keys_str_mv | AT pooriasafarzadehkozani novelantigensofcartcelltherapynewroadsolddestination AT pouyasafarzadehkozani novelantigensofcartcelltherapynewroadsolddestination AT fatemehrahbarizadeh novelantigensofcartcelltherapynewroadsolddestination |